Creo Medical (LSE:CREO) reported a strong first-half performance for 2026, with revenue increasing 45% year-on-year to £3.2 million as demand for its advanced medical technology portfolio continued to grow.
The company also made further progress in improving operational efficiency, reducing operating costs by 15% during the first six months of the year. As a result, its operating loss narrowed by more than 25%, reflecting the benefits of cost-saving initiatives alongside higher sales.
Revenue growth was supported by increased adoption of key products, including Speedboat, SpydrBlade Flex and MicroBlate Fine. Creo Medical also expanded its commercial presence into new international markets, with particularly strong progress across Latin America.
Management continued to streamline the business by scaling its commercial platform, simplifying operations and outsourcing manufacturing activities, helping to create a leaner operating model while supporting future growth.
The company reaffirmed its full-year revenue growth guidance of between 50% and 60%. Management said a healthy order book, together with revenue expected to be weighted toward the second half of the year, provides confidence in achieving that target. Creo Medical also believes its lower cost base and recent financing activities will support its progress towards profitability.
Leave a Reply